To determine the relative efficacy of usual medical care and a course of treatment by thermal
biofeedback in reducing vasospastic attacks characteristic of Raynaud's syndrome. Also, to
confirm the frequency and severity of attacks, examine the role of psychophysiological
factors in precipitating attacks, and assess the influence of treatment on health quality of
life.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
National Heart, Lung, and Blood Institute (NHLBI)
Treatments:
Nifedipine
Criteria
Men and women with documented primary or secondary Raynaud's syndrome.